---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-138263"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:08:17.343351+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio Q1 net loss $14.8M; completes AnHeart acquisition; cash $597M

## Summary
- Net loss of $14.8M ($0.07 per share) vs $21.7M ($0.10) in Q1 2023.
- Cash, equivalents and marketable securities of $597.0M as of March 31, 2024.
- Acquisition of AnHeart Therapeutics closed in April 2024, transforming Nuvation into late-stage global oncology company.
- Appointed Colleen Sjogren as Chief Commercial Officer; first patient dosed in Phase 1/2 study of NUV-1511 DDC.
- Updated taletrectinib Phase 2 TRUST-I data to be presented at ASCO 2024.

## SEC filing metadata
- accession: 0001193125-24-138263
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312524138263/0001193125-24-138263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312524138263/d693344d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-138263
- JSON: https://secwatch.observer/filing/0001193125-24-138263.json
- Plain text: https://secwatch.observer/filing/0001193125-24-138263.txt

## Key facts
- Earnings Releases
  Nuvation Bio Inc. reported the first quarter ended March 31, 2024 results: net income $14.8 million, EPS $(0.07) per share.
  - Period: the first quarter ended March 31, 2024
  - Net income: $14.8 million
  - EPS: $(0.07) per share
  - Result: reported results
  source text: For the three months ended March 31, 2024, Nuvation Bio reported a net loss of $14.8 million, or $(0.07) per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811063/000119312524138263/0001193125-24-138263-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.